Implicity’s, a pioneer in remote patient monitoring and cardiac data management, announced today that a revolutionary medical algorithm that analyzes ECG data from ILR (Implantable Loop Recorders) has received FDA approval. The recently cleared ILR ECG Analyzer is an artificial intelligence-based technology that represents a milestone in the cardiology field.
As we develop in the US market, this is a crucial milestone for Implicity’s,” stated Dr. Arnaud Rosier, CEO and creator of Implicity’s. “Now that our AI product has received FDA approval, it may be used in conjunction with implanted loop recorders to enhance arrhythmia detection and save electrophysiologists and their teams’ time evaluating non-actionable events.”
The ILR ECG Analyzer from Implicity’s adds AI to the cardiac rhythm data obtained by the Medtronic models. The digital medical gadget will be incorporated into cardiac remote monitoring platform to provide electrophysiology teams with a unique value proposition by adding extra signal processing and analysis to increase the accuracy of abnormal heartbeat identification.